VILLA GUARDIA, Italy, Aug. 9 Gentium S.p.A. (Nasdaq: GENT) (the "Company") today announced that will publish financials for the first half of 2010 on Thursday, August 12, 2010, and hold a conference call and live webcast 8:30 a.m. ET / 2:30 p.m. CET that day to discuss the results and provide a business update. A press release detailing the results will be published prior to the call. To participate in the call, interested parties may dial 1-877-312-9401 (North America toll-free) or 1-224-357-2660 (international/toll) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.gentium.it.
The call will be archived for replay for 30 days. The replay can be accessed on the Company's website, http://www.gentium.it or at 1-800-642-1687 (North America toll-free) or 1-706-645-9291 (international/toll) using Conference ID 93593929.
Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status by the U.S. FDA and Orphan Medicinal Product Designation by the European Commission both to treat and to prevent VOD and Fast Track Designation by the U.S. FDA to treat VOD.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results, including with respect to any financial forecast or the possibility of any future regulatory approval, may differ materially from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in our Form 20-F filed with the Securities and Exchange Commission under the caption "Risk Factors."
CONTACT: Christine Labaree, 646 378 2951
SOURCE Gentium S.p.A.